Decreased function of this transporter, inherited through genetic variability, or altered statin exposure due to drug interactions in individuals who phenotypically have decreased or poor SLCO1B1 function, results in increased systemic exposure to statins, thus increasing the risk of SAMS. The gene discussed is SLCO1B1; the disease is short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.